Inhale To Initiate 10 Proprietary Programs In Two Years, Keep Partner Model
Executive Summary
Inhale Therapeutics expects to begin 10 proprietary research programs in the next two years
You may also be interested in...
Amgen To Position Neulasta As Prophylaxis For Febrile Neutropenia
Amgen plans to position the Neupogen follow-on product Neulasta as prophylaxis for infection related to chemotherapy-induced neutropenia
Pfizer Pregabalin NDA Will Include Anxiety Use; Filing Date Pushed To 2002
Pfizer's updated pregabalin NDA filing schedule calls for three initial indications - add-on epilepsy, neuropathic pain and generalized anxiety disorder - to be submitted in 2002
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011